Effect of Rivastigmine in Electroconvulsive therapy (ECT)-induced cognitive disorders

Evaluating effects of Rivastigmine in Electroconvulsive therapy-induced cognitive side effects in patients receiving Electroshock; A Randomized double blind placebo-controled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200122046225N1

Enrollment

Registered

2020-05-18

Start date

2020-09-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ECT, Electroconvulsive therapy, Electroshock, ECT-induced Cognitive Disorders, ECT-induced Memory Disorder, Rivastigmine, Cholinesterase Inhibitors, MoCA, ACE, Effect of Rivastigmine on Cognitive Impairment After ECT, Effect of cholinesterase inhibitiors on cognitive impairments after electroconvulsive therapy, effect of Rivastigmine on memory.

Interventions

Intervention 1: Intervention group: 1.5mg and 3mg rivastigmine capsules produced by Hakim Pharmaceutical Company. Rivastigmine Will be given to the patients initially 1.5mg twice daily for 2 weeks an

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients over than 18 years and less than 70 years Patients with diagnosis of BMD & Schizophrenia who are candidates for ECT Psychiatric diagnosis of patients based on DSM IV, SCIDP criteria Patients with refractory treatment and candidate for ECT Resistance to at least 2 antipsychotics for 6 weeks at a equivalent dose of 1000 mg chlorpromazine Patients with cognitive decline with electroshock diagnosed by neuroscientist and under cognitive evaluation by ACE, MoCA

Exclusion criteria

Exclusion criteria: Patients with a history of previous neurologic disease include Stroke and Parkinson's disease Patients with a history of previous cognitive impairment and dementia Patients with heart block and arrhythmia Patients with a history of severe gastrointestinal disorders and gastrointestinal bleeding History of serious medical illness present use of substances

Design outcomes

Primary

Measure	Time frame
Montreal Cognitive Assessment Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Montreal Cognitive Assessment Test Questionnaire.;Addenbrooke's Cognitive Examination Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Addenbrooke's Cognitive Examination Questionnaire.	—

Measure

Time frame

Montreal Cognitive Assessment Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Montreal Cognitive Assessment Test Questionnaire.;Addenbrooke's Cognitive Examination Score. Timepoint: Before receiving the first ECT session, after receiving the last session and 1 month after the beginning of intervention and finally 3 months after that. Method of measurement: Addenbrooke's Cognitive Examination Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Salimi

Tehran University of Medical Sciences

hossein.salimi.1375@gmail.com+98 21 4417 9132

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026